- ISIN
- US07725L1026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 3, 2016
Highlights
- Market Cap
- $31.47B
- Enterprise Value
- $27.96B
- EPS (TTM)
- $4.49
- PE Ratio
- 60.48
- Total Revenue (TTM)
- $5.74B
- Gross Profit (TTM)
- $5.07B
- EBITDA (TTM)
- $954.09M
- Year Range
- $239.25 - $385.22
- Target Price
- $401.13
- ROA (TTM)
- 6.00%
- ROE (TTM)
- 10.78%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ONC Performance Chart
BeOne Medicines Ltd (ONC) is down 10.5% since the beginning of the year. At $272 per share, ONC is trading 29.4% below its 52-week high of $385. Investors who bought $1,000 worth of ONC shares 5 years ago would now be looking at an investment worth $794.
Loading charts...
Returns By Period
BeOne Medicines Ltd (ONC) has returned -10.54% so far this year and 10.00% over the past 12 months. Looking at the last ten years, ONC has achieved an annualized return of 25.41%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.
BeOne Medicines Ltd
- 1D
- 0.61%
- 1M
- -12.39%
- YTD
- -10.54%
- 6M
- -13.26%
- 1Y
- 10.00%
- 3Y*
- 14.88%
- 5Y*
- -4.50%
- 10Y*
- 25.41%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ONC Monthly Returns History
Based on dividend-adjusted daily data since Feb 3, 2016, ONC's average daily return is +0.15%, while the average monthly return is +2.82%. At this rate, an investment would double in approximately 2.1 years.
Historically, 52% of months were positive and 48% were negative. The best month was Jul 2017 with a return of +56.6%, while the worst month was Oct 2018 at -26.9%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ONC closed higher 51% of trading days. The best single day was Nov 1, 2019 with a return of +37.0%, while the worst single day was May 11, 2022 at -15.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.04% | -6.87% | -6.32% | -0.57% | -2.49% | -5.60% | -10.54% | ||||||
| 2025 | 21.81% | 20.81% | 0.14% | -4.54% | -5.48% | -1.43% | 24.40% | 1.63% | 11.32% | -8.87% | 9.70% | -10.80% | 64.48% |
| 2024 | -17.81% | 11.75% | -5.59% | -1.57% | -3.31% | -4.15% | 16.76% | 15.13% | 17.07% | -9.74% | 6.10% | -14.09% | 2.41% |
| 2023 | 16.40% | -12.25% | -4.05% | 18.29% | -13.35% | -19.30% | 20.15% | -3.11% | -13.34% | 3.56% | 0.35% | -3.52% | -18.00% |
| 2022 | -10.46% | -13.22% | -10.41% | -15.16% | -14.24% | 17.95% | 3.85% | 2.13% | -21.46% | 25.27% | 13.45% | 14.79% | -18.82% |
| 2021 | 23.84% | 0.00% | 8.77% | -1.30% | 4.36% | -4.27% | -7.75% | -2.62% | 17.74% | -1.45% | -2.85% | -22.04% | 4.85% |
Benchmark Metrics
BeOne Medicines Ltd has an annualized alpha of 26.75%, beta of 0.89, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since February 03, 2016.
- This stock captured 106.51% of S&P 500 Index gains but only 58.64% of its losses - a favorable profile for investors.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 26.75%
- Beta
- 0.89
- R²
- 0.08
- Upside Capture
- 106.51%
- Downside Capture
- 58.64%
Return for Risk
Risk / Return Rank
ONC ranks 49 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BeOne Medicines Ltd (ONC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ONC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.79 | ||
| Sortino ratioReturn per unit of downside risk | -2.10 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.37 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | 0.32 | 2.78 | -2.46 |
| Martin ratioReturn relative to average drawdown | 0.69 | 12.44 | -11.75 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BeOne Medicines Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BeOne Medicines Ltd was 69.96%, occurring on May 11, 2022. The portfolio has not yet recovered.
The current BeOne Medicines Ltd drawdown is 32.58%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -69.96%May 2022 | 7mo 23d | — | 4y 9moSep 2021 - now |
Rate-hike selloffLate 2018 | -50.63%Oct 2018 | 4mo 20d | 1y 8mo | 2y 1moJun 2018 - Jul 2020 |
2021 bear market2021 | -34.68%Aug 2021 | 6mo 4d | 27d | 7mo 1dFeb 2021 - Sep 2021 |
2017 bear market2017 | -30.62%Nov 2017 | 1mo 4d | 2mo 5d | 3mo 9dOct 2017 - Jan 2018 |
2020 bear market2020 | -30.10%Dec 2020 | 1mo 15d | 1mo 12d | 2mo 27dOct 2020 - Jan 2021 |
Drawdown Indicators
| ONC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.96% | -56.78% | -13.18% |
Max Drawdown (1Y)Largest decline over 1 year | -31.05% | -9.10% | -21.95% |
Max Drawdown (3Y)Largest decline over 3 years | -42.47% | -18.90% | -23.57% |
Max Drawdown (5Y)Largest decline over 5 years | -69.96% | -25.43% | -44.53% |
Max Drawdown (10Y)Largest decline over 10 years | -69.96% | -33.92% | -36.04% |
Current DrawdownCurrent decline from peak | -32.58% | -1.80% | -30.78% |
Average DrawdownAverage peak-to-trough decline | -29.63% | -10.71% | -18.92% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.54% | 2.03% | +12.51% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BeOne Medicines Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BeOne Medicines Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ONC, comparing it with other companies in the Biotechnology industry. Currently, ONC has a P/E ratio of 60.5. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ONC relative to other companies in the Biotechnology industry. Currently, ONC has a P/S ratio of 5.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ONC in comparison with other companies in the Biotechnology industry. Currently, ONC has a P/B value of 6.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ONC
Add BeOne Medicines Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ONC